Pancreatic Cancer Research

ResearcherUniversity of California, San FranciscoActive in the last 2 years

Adnan A. Alseidi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-0365-1955; OpenAlex author ID A5011775817, A5036872391. Sources: OpenAlex.

Their work

Papers
32 (first author 2, last author 2)
Trials
0
Grants
0
Labs led
0
Collaborators
143
Papers, trials and grants by year

2014: 2 papers · 2015: 1 paper · 2016: none · 2017: 2 papers · 2018: 3 papers · 2019: 1 paper · 2020: 6 papers · 2021: 3 papers · 2022: none · 2023: 3 papers · 2024: 4 papers · 2025: 3 papers · 2026: 4 papers

Papers 32

  1. Impact of adjuvant chemotherapy among pathologic complete responders with pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ejso.2026.111955↗
  2. A Computer Vision Algorithm to Predict Superior Mesenteric Artery Margin Status for Patients With Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1097/sla.0000000000006506↗
  3. Re-evaluating the Role of Neoadjuvant Chemotherapy in Early-Stage Pancreatic Ductal Adenocarcinoma: Unveiling the Impact of Immortal Time Bias on Survival. Co-author DOI 10.1245/s10434-026-19829-1↗
  4. ASO Visual Abstract: Re-evaluating the Role of Neoadjuvant Chemotherapy in Early-Stage Pancreatic Ductal Adenocarcinoma: Unveiling the Impact of Immortal Time … Co-author DOI 10.1245/s10434-026-19921-6↗
  5. Adjuvant Chemotherapy After Resection of Localized Pancreatic Adenocarcinoma Following Preoperative FOLFIRINOX. Co-author DOI 10.1001/jamaoncol.2024.5917↗
  6. Validation of the PANAMA Score for Survival and Benefit of Adjuvant Therapy in Patients With Resected Pancreatic Cancer after Neoadjuvant FOLFIRINOX. Co-author DOI 10.1097/sla.0000000000006650↗
  7. Ongoing Failure to Deliver Guideline-Concordant Care for Patients with Pancreatic Cancer. Co-author DOI 10.3390/cancers17020170↗
  8. The value of splenectomy during left-sided pancreatectomy for pancreatic ductal adenocarcinoma: predefined subanalysis in the DIPLOMA randomized trial. Co-author DOI 10.1093/bjs/znae236↗
  9. Long-Duration Neoadjuvant Therapy with FOLFIRINOX Yields Favorable Outcomes for Patients Who Undergo Surgery for Pancreatic Cancer. Co-author DOI 10.1245/s10434-024-15579-0↗
  10. Distinct Indications for Adjuvant Therapy in Resected Invasive Mucinous Cystic Neoplasms of the Pancreas Compared with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-024-15841-5↗
  11. Adult Pancreatoblastoma: Clinical Insights and Outcomes Compared to Pancreatic Ductal Adenocarcinoma (PDAC). Co-author DOI 10.3390/curroncol31090370↗
  12. Minimally invasive versus open distal pancreatectomy for resectable pancreatic cancer (DIPLOMA): an international randomised non-inferiority trial. Co-author DOI 10.1016/j.lanepe.2023.100673↗
  13. Surgical and Oncological Outcomes After Preoperative FOLFIRINOX Chemotherapy in Resected Pancreatic Cancer: An International Multicenter Cohort Study. Co-author DOI 10.1245/s10434-022-12387-2↗
  14. Consensus Statement on the Use of Near-Infrared Fluorescence Imaging during Pancreatic Cancer Surgery Based on a Delphi Study: Surgeons' Perspectives on Curren… Co-author DOI 10.3390/cancers15030652↗
  15. Laparoscopic versus open extended radical left pancreatectomy for pancreatic ductal adenocarcinoma: an international propensity-score matched study. Co-author DOI 10.1007/s00464-020-08206-y↗
  16. Minimally invasive versus open distal pancreatectomy for pancreatic ductal adenocarcinoma (DIPLOMA): study protocol for a randomized controlled trial. Co-author DOI 10.1186/s13063-021-05506-z↗
  17. Predictors for Survival in an International Cohort of Patients Undergoing Distal Pancreatectomy for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-020-08658-5↗
  18. Evaluation of Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer After Neoadjuvant FOLFIRINOX Treatment. Co-author DOI 10.1001/jamaoncol.2020.3537↗
  19. International validation and update of the Amsterdam model for prediction of survival after pancreatoduodenectomy for pancreatic cancer. Co-author DOI 10.1016/j.ejso.2019.12.023↗
  20. Preoperative imaging characteristics predict poor survival and inadequate resection for left-sided pancreatic adenocarcinoma: a multi-institutional analysis. Last author DOI 10.1016/j.hpb.2019.12.012↗
  21. Gemcitabine/nab-paclitaxel with pamrevlumab: a novel drug combination and trial design for the treatment of locally advanced pancreatic cancer. First author DOI 10.1136/esmoopen-2019-000668↗
  22. Impact of Neoadjuvant Therapy in Resected Pancreatic Ductal Adenocarcinoma of the Pancreatic Body or Tail on Surgical and Oncological Outcome: A Propensity-Sco… Co-author DOI 10.1245/s10434-019-08137-6↗
  23. Sustained Carbohydrate Antigen 19-9 Response to Neoadjuvant Chemotherapy in Borderline Resectable Pancreatic Cancer Predicts Progression and Survival. Co-author DOI 10.1634/theoncologist.2019-0878↗
  24. Significance of radiographic splenic vessel involvement in the pancreatic ductal adenocarcinoma of the body and tail of the gland. Co-author DOI 10.1002/jso.25498↗
  25. Initiation of adjuvant therapy following surgical resection of pancreatic ductal adenocarcinoma (PDAC): Are patients from rural, remote areas disadvantaged? Co-author DOI 10.1002/jso.25060↗
  26. Does mesenteric venous imaging assessment accurately predict pathologic invasion in localized pancreatic ductal adenocarcinoma? Co-author DOI 10.1016/j.hpb.2018.03.014↗
  27. Gemcitabine and Taxane Adjuvant Therapy with Chemoradiation in Resected Pancreatic Cancer: A Novel Strategy for Improved Survival? Co-author DOI 10.1245/s10434-018-6334-8↗
  28. Localized pancreatic cancer with positive peritoneal cytology as a sole manifestation of metastatic disease: a single-institution experience. Co-author DOI 10.1016/j.amjsurg.2016.04.008↗
  29. Five-Year Actual Overall Survival in Resected Pancreatic Cancer: A Contemporary Single-Institution Experience from a Multidisciplinary Perspective. Co-author DOI 10.1245/s10434-016-5716-z↗
  30. Multidisciplinary management of locally advanced pancreatic ductal adenocarcinoma. First author DOI 10.1067/j.cpsurg.2015.07.003↗
  31. Posterior 'superior mesenteric artery first' approach for resection of locally advanced pancreatic cancer. Co-author DOI 10.1245/s10434-013-3431-6↗
  32. Extended neoadjuvant chemotherapy for borderline resectable pancreatic cancer demonstrates promising postoperative outcomes and survival. Co-author DOI 10.1245/s10434-014-3486-z↗

Closest collaborators

The 25 strongest of 143 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Mohamed A. Adam · 8 shared papers, 2024–2026 · strength 1.91
  2. Eric K. Nakakura · 7 shared papers, 2024–2026 · strength 1.67
  3. Amir Ashraf‐Ganjouei · 4 shared papers, 2024–2026 · strength 0.95
  4. Kimberly Saunders Kirkwood · 4 shared papers, 2024–2026 · strength 0.86
  5. Flavio G. Rocha · 11 shared papers, 2014–2020 · strength 0.84
  6. Jane Wang · 4 shared papers, 2024–2026 · strength 0.83
  7. Sophia Hernandez · 3 shared papers, 2025–2026 · strength 0.82
  8. Tobias Keck · 7 shared papers, 2020–2025 · strength 0.71
  9. Marc G. Besselink · 7 shared papers, 2020–2025 · strength 0.71
  10. Thilo Hackert · 6 shared papers, 2020–2025 · strength 0.68
  11. Massimo Falconi · 6 shared papers, 2020–2025 · strength 0.66
  12. Vincent J. Picozzi · 8 shared papers, 2014–2020 · strength 0.61
  13. Amir Ashraf · 2 shared papers, 2026 · strength 0.58
  14. Ajay V. Maker · 3 shared papers, 2024 · strength 0.57
  15. Mohammad Abu Hilal · 6 shared papers, 2020–2024 · strength 0.56
  16. Giovanni Butturini · 5 shared papers, 2020–2025 · strength 0.53
  17. Bas Groot Koerkamp · 5 shared papers, 2020–2025 · strength 0.52
  18. Giuseppe Malleo · 5 shared papers, 2020–2025 · strength 0.49
  19. Gianpaolo Balzano · 4 shared papers, 2020–2025 · strength 0.44
  20. Roberto Salvia · 4 shared papers, 2020–2025 · strength 0.44
  21. Maarten Korrel · 4 shared papers, 2020–2024 · strength 0.41
  22. Ugo Boggi · 4 shared papers, 2020–2024 · strength 0.41
  23. Jony van Hilst · 4 shared papers, 2020–2024 · strength 0.41
  24. William Scott Helton · 5 shared papers, 2015–2020 · strength 0.39
  25. Richard A. Kozarek MD · 5 shared papers, 2017–2019 · strength 0.38

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.